Methods for the treatment of Kaposi's sarcoma or KSHV-induced lymphoma using immunomodulatory compounds, and uses of biomarkers

US10001483B2 · kind B2 · utility

Assignees

• CELGENE CORPORATION · US
• The United States of America, as represented by the Secretary, Department of Health and Human Services · US

Inventors

• Robert Yarchoan · Bethesda, US
• Jerome B. Zeldis · Princeton, US
• Mark N. Polizzotto · Forbes, AU
• David Anak Simon Davis · Belconnen, AU
• Irini Sereti · Washington, US
• Thomas Uldrick · Washington, US
• Denise Whitby · Frederick, US
• Vikram Khetani · Bound Brook, US

Key dates

• Filing date: Jun 24, 2016
• Grant date: Jun 19, 2018
• Expiry date: Jun 24, 2036

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2800/52
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided herein are uses of gene and protein biomarkers as a predictor of clinical sensitivity of Kaposi's sarcoma (KS) or Kaposi's sarcoma-associated herpesvirus (KSHV) induced lymphoma and patient response to treatment with an immunomodulatory compound. Further provided herein are methods for the treatment or management of Kaposi's sarcoma or KSHV-induced lymphoma with an immunomodulatory compound, alone or in combination with doxorubicin.